Drug Detail

Information about Ganetespib

Generic Name
Brand Name (US)
Drug Type
HSP90 inhibitor
Approval Status
Phase 2
Overall Strategy
KIT Protein Based
Destroy KIT
Drug Category
HSP90 inhibitor

STA-9090 is an HSP-90 inhibitor. According to the Synta press release, in preclinical studies “STA-9090 has shown the ability to inhibit multiple kinases with comparable potency to, and a broader activity profile than specific kinase inhibitors such as Gleevec, Tarceva and Sutent. In addition, STA-9090 has shown potency ten to 100 times greater than the geldanamycin family of Hsp90 inhibitors, as well as activity against a wider range of kinases. In in vivo models, STA-9090 has shown strong efficacy in a wide range of cancer types, including cancers resistant to Gleevec, Tarceva, and Sutent.”
Medical News TODAY reports: "Along with work presented by Dr. Shapiro's lab, we and our collaborators have shown broad activity of STA-9090 against multiple cancer types, including both cancers that are sensitive to kinase inhibitors, such as Gleevec and Sutent, and cancers that are resistant to those kinase inhibitors. These collective results have shown that STA-9090 is differentiated within the Hsp90 inhibitor class, including improved potency and reduced toxicity compared to the 17-AAG family of inhibitors."



Press release - Synta initiates phase 2 clinical trial of STA-9090 in GIST following failure of Gleevec and Sutent


Synta drug information page


Premeire Oncology STA-9090 trial information


Results differentiate STA-9090 in Hsp90 inhibitor class and show activity in erlotinib-resistant lung cancer models


Reuters article about Synta starting a third phase I trial


Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090


Reuters article about Synta starting second phase I trial


CTOS 2009 Poster: In Vitro and In Vivo Efficacy of the Novel Hsp90 Inhibitor STA-9090 (PDF)

Trials of this drug


Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors


Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors


A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Trial results

  Results published at clinicaltrials.gov
  2011, Synta press release - Synta Announces Presentation of Additional Ganetespib Results at ASCO
  ASCO 2010 - A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.
  ASCO 2010 - A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors.
  ASCO 2011 - An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

Search for this drug/combination in: